Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement

The severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID‐19). Patients with cardiovascular (CV) risk fac...

Full description

Saved in:
Bibliographic Details
Published in:CA: a cancer journal for clinicians 2020-11, Vol.70 (6), p.480-504
Main Authors: Lenihan, Daniel, Carver, Joseph, Porter, Charles, Liu, Jennifer E., Dent, Susan, Thavendiranathan, Paaladinesh, Mitchell, Joshua D., Nohria, Anju, Fradley, Michael G., Pusic, Iskra, Stockerl‐Goldstein, Keith, Blaes, Anne, Lyon, Alexander R., Ganatra, Sarju, López‐Fernández, Teresa, O'Quinn, Rupal, Minotti, Giorgio, Szmit, Sebastian, Cardinale, Daniela, Alvarez‐Cardona, Jose, Curigliano, Giuseppe, Neilan, Tomas G., Herrmann, Joerg
Format: Article
Language:English
Subjects:
Anthracyclines - adverse effects
Antineoplastic Agents - adverse effects
best practice
Cancer
cardiac safety
Cardiovascular diseases
Cardiovascular Diseases - diagnostic imaging
Cardiovascular Diseases - etiology
Cardiovascular Diseases - therapy
cardio‐oncology
Coronaviridae
coronavirus disease 2019 (COVID‐19)
Coronaviruses
COVID-19
COVID-19 - complications
COVID-19 - physiopathology
COVID-19 - prevention & control
COVID-19 - transmission
Cross Infection - prevention & control
Epidemics
Humans
Neoplasms - complications
Neoplasms - therapy
Oncology
pandemic
Pandemics
Patients
Proteasome Inhibitors - adverse effects
Protein Kinase Inhibitors - adverse effects
Radiotherapy - adverse effects
Receptor, ErbB-2 - antagonists & inhibitors
recommendations
Referral and Consultation
Risk factors
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Trastuzumab - adverse effects
virus
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome coronavirus 2 (SARS–CoV‐2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID‐19). Patients with cardiovascular (CV) risk factors and established CV disease (CVD) are among those initially identified at the highest risk for serious complications, including death. Subsequent studies have pointed out that patients with cancer are also at high risk for a critical disease course. Therefore, the most vulnerable patients are seemingly those with both cancer and CVD, and a careful, unified approach in the evaluation and management of this patient population is especially needed in times of the COVID‐19 pandemic. This review provides an overview of the unique implications of the viral outbreak for the field of cardio‐oncology and outlines key modifications in the approach to this ever‐increasing patient population. These modifications include a shift toward greater utilization of cardiac biomarkers and a more focused CV imaging approach in the broader context of modifications to typical practice pathways. The goal of this strategic adjustment is to minimize the risk of SARS–CoV‐2 infection (or other future viral outbreaks) while not becoming negligent of CVD and its important impact on the overall outcomes of patients who are being treated for cancer.
ISSN:0007-9235
1542-4863
DOI:10.3322/caac.21635